Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Bronchiectasis is a condition where the bronchial tubes of your lungs are permanently damaged, widened, and thickened. These damaged air passages allow bacteria and mucus to build up and pool in ...

This activity is provided by National Jewish Health. Non-cystic fibrosis bronchiectasis (NCFBE) is a progressive pulmonary condition that leads to bronchial wall damage and irreversible bronchial ...

Researchers obtained bronchiectasis diagnosis and severity using thorax high-resolution CT, the Smith radiology scale and the Bhalla scoring system. Then, the researchers analyzed clinical data ...

A once-daily oral therapy targeting neutrophilic inflammation has shown promise in reducing exacerbations in patients with ...

Bronchiectasis is a lung condition that causes a persistent cough and excess phlegm, or sputum. It is a permanent condition that gets worse over time. It can be fatal. The bronchi dilate, usually ...

Panelists discuss how ideal candidates for bronchiectasis surgery have localized disease on CT scan and bronchoscopy, adequate pulmonary function (orced expiratory volume in 1 second > 40%), and ...

A total of 1,680 adults and 41 adolescents were randomly assigned to brensocatib or placebo. The researchers found that the annualized rate of pulmonary exacerbations was 1.02, 1.04, and 1.29 in ...

Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. New England Journal of Medicine , 2025; 392 (16): 1569 DOI: 10.1056/NEJMoa2411664 Cite This Page : ...

Brensocatib reduces the annualized rate of pulmonary exacerbations in patients with bronchiectasis compared to placebo, with rate ratios of 0.79 and 0.81 for 10 mg and 25 mg doses, respectively.